Does apixaban reduce stroke or systemic embolism in patients with subclinical atrial fibrillation?
Patients with subclinical atrial fibrillation
Apixaban
Aspirin
Stroke or systemic embolismhard clinical
In patients with subclinical atrial fibrillation, apixaban reduces the risk of stroke or systemic embolism compared to aspirin, but increases the risk of major bleeding.
Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. (Funded by the Canadian Institutes of Health Research and others; ARTESIA ClinicalTrials.gov number, NCT01938248.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Jeff S. Healey
Renato D. Lópes
Christopher B. Granger
New England Journal of Medicine
Duke University
Karolinska Institutet
Michigan State University
Building similarity graph...
Analyzing shared references across papers
Loading...
Healey et al. (Sun,) studied this question.
www.synapsesocial.com/papers/69cbea344dc32b50d7af5e9d — DOI: https://doi.org/10.1056/nejmoa2310234